Cost and cost-effectiveness of immunotherapy in childhood ALL: A systematic review

被引：1

作者：

Scoleri-Longo, Yolanda ^{[1
]}

Pechlivanoglou, Petros ^{[2
]}

Gupta, Sumit ^{[3
,4
,5
,6
]}

机构：

[1] Hosp Sick Children, Dept Paediat, Post Grad Med Educ, Toronto, ON, Canada

[2] Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G1X8, Canada

[3] Inst Clin Evaluat Sci, Canc Res Program, Toronto, ON, Canada

[4] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada

[5] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada

[6] Univ Toronto, Fac Med, Toronto, ON, Canada

来源：

EJHAEM | 2024年 / 5卷 / 01期

关键词：

acute lymphoblastic leukemia; cancer; child; cost-effectiveness; immunotherapy; systematic review; ACUTE LYMPHOBLASTIC-LEUKEMIA; YOUNG-ADULT PATIENTS; SURVIVAL; CHILDREN; TISAGENLECLEUCEL; ADOLESCENTS;

D O I：

10.1002/jha2.814

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Survival rates for pediatric acute lymphoblastic leukemia (pALL) have improved dramatically; relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) remains challenging. Immunotherapies are rapidly evolving treatments for r/r ALL with limited cost-effectiveness data. This study identifies existing economic evaluations of immunotherapy in pALL and summarizes cost-effectiveness. Medline, Embase, and other databases were searched from inception to October 2022. Cost-effectiveness analyses evaluating immunotherapy in pALL were included. Costs reported in 2021 USD. Of 2960 studies, 11 met inclusion criteria. Tisagenlecleucel was compared to standard of care, clofarabine monotherapy, clofarabine combination therapy, or blinatumomab. No studies have evaluated blinatumomab or inotuzumab ozogamicin. Six studies found tisagenlecleucel to be cost-effective, five of which were supported by Novartis. Four found that it had the potential to be cost-effective, and one found that it was not cost-effective. The cost-effectiveness of tisagenlecleucel was highly dependent on list price and cure rates. This study can inform the use of tisagenlecleucel in pALL. This study identifies existing economic evaluations of immunotherapy in pALL and summarizes cost-effectiveness. Six studies found tisagenlecleucel to be cost-effective, five of which were supported by Novartis. Cost-effectiveness of tisagenlecleucel was highly dependent on list price and cure rates. This study can inform the use of tisagenlecleucel in pALL. image .

引用

页码：166 / 177

页数：12

共 34 条

[11] Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States [J].

Delea, Thomas E. ;

Zhang, Xinke ;

Amdahl, Jordan ;

Boyko, Diana ;

Dirnberger, Franziska ;

Campioni, Marco ;

Cong, Ze .

PHARMACOECONOMICS, 2019, 37 (09) :1177-1193

[12] Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia [J].

Elitzur, Sarah ;

Arad-Cohen, Nira ;

Barzilai-Birenboim, Shlomit ;

Ben-Harush, Miriam ;

Bielorai, Bella ;

Elhasid, Ronit ;

Feuerstein, Tamar ;

Gilad, Gil ;

Gural, Alexander ;

Kharit, Mira ;

Litichever, Naomi ;

Nirel, Ronit ;

Weinreb, Sigal ;

Wolach, Ofir ;

Toren, Amos ;

Izraeli, Shai ;

Jacoby, Elad .

PEDIATRIC BLOOD & CANCER, 2019, 66 (10)

[13] Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria [J].

Evers, S ;

Goossens, M ;

de Vet, H ;

van Tulder, M ;

Ament, A .

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2005, 21 (02) :240-245

[14] Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada [J].

Furzer, Jill ;

Gupta, Sumit ;

Nathan, Paul C. ;

Schechter, Tal ;

Pole, Jason D. ;

Krueger, Joerg ;

Pechlivanoglou, Petros .

JAMA ONCOLOGY, 2020, 6 (03) :393-401

[15] Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future [J].

Heine, Renaud ;

Thielen, Frederick W. ;

Koopmanschap, Marc ;

Kersten, Marie Jose ;

Einsele, Hermann ;

Jaeger, Ulrich ;

Sonneveld, Pieter ;

Sierra, Jorge ;

Smand, Carin ;

Uyl-de Groot, Carin A. .

HEMASPHERE, 2021, 5 (02)

[16] Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study [J].

Kantarjian, Hagop M. ;

DeAngelo, Daniel J. ;

Stelljes, Matthias ;

Liedtke, Michaela ;

Stock, Wendy ;

Goekbuget, Nicola ;

O'Brien, Susan M. ;

Jabbour, Elias ;

Wang, Tao ;

White, Jane Liang ;

Sleight, Barbara ;

Vandendries, Erik ;

Advani, Anjali S. .

CANCER, 2019, 125 (14) :2474-2487

[17] Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial [J].

Laetsch, Theodore W. ;

Maude, Shannon L. ;

Rives, Susana ;

Hiramatsu., Hidefumi ;

Bittencourt., Henrique ;

Bader, Peter. ;

Baruchel, Andre ;

Boyer, Michael ;

De Moerloose, Barbara ;

Qayed, Muna ;

Buechner, Jochen ;

Pulsipher, Michael A. ;

Myers, Gary Douglas ;

Stefanski, Heather E. ;

Martin, Paul L. ;

Nemecek, Eneida ;

Peters, Christina ;

Yanik, Gregory ;

Khaw, Seong Lin ;

Davis, Kara L. ;

Krueger, Joerg ;

Balduzzi, Adriana ;

Boissel, Nicolas ;

Tiwari, Ranjan ;

O'Donovan, Darragh ;

Grupp, Stephan A. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) :1664-+

[18] Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia [J].

Lin, John K. ;

Lerman, Benjamin J. ;

Barnes, James I. ;

Boursiquot, Brian C. ;

Tan, Yuan Jin ;

Robinson, Alex Q. L. ;

Davis, Kara L. ;

Owens, Douglas K. ;

Goldhaber-Fiebert, Jeremy D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) :3192-+

[19] The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia [J].

Lin, Yu-Feng ;

Lairson, David R. ;

Chan, Wenyaw ;

Du, Xianglin L. ;

Leung, Kathryn S. ;

Kennedy-Nasser, Alana A. ;

Martinez, Caridad A. ;

Gottschalk, Stephen M. ;

Bollard, Catherine M. ;

Heslop, Helen E. ;

Brenner, Malcolm K. ;

Krance, Robert A. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (09) :1272-1281

[20] Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland [J].

Moradi-Lakeh, Maziar ;

Yaghoubi, Mohsen ;

Seitz, Patrick ;

Javanbakht, Mehdi ;

Brock, Elisabeth .

ADVANCES IN THERAPY, 2021, 38 (06) :3427-3443

← 1 2 3 4 →